



Curriculum Vitae

Personal information **Fátima Ventura**

Work experience

1. Employer: INFARMED – National Authority of Medicines and Health Products I.P.
 - Start date: 042025
 - End date:
 - Position: Head of Unit, Medicines Evaluation Department/Centralised Procedure Unit
 - Activities: Coordinator of all the activities regarding CHMP and related WPs
 - Country: Portugal
2. Employer: General Health Directorate
 - Start date: 112020
 - End date: 102025
 - Position: Representative of Infarmed
 - Activities: Representative of Infarmed at the Portuguese NITAG for COVID_19 and Flu vaccines: input from regulatory perspectives and status of COVID_19 and Flu vaccines and contribution to advice on national recommendations for COVID_19 and Flu vaccination
 - Country: Portugal
3. Employer: INFARMED – National Authority of Medicines and Health Products I.P.
 - Start date: 032017
 - End date: 032025
 - Position: Head of Unit, Medicines Evaluation Department/Scientific Evaluation Unit
 - Activities:
 - Country: Portugal
4. Employer: INFARMED – National Authority of Medicines and Health Products I.P.
 - Start date: 032016
 - End date:
 - Position: Quality Assessor
 - Activities: Internal quality assessor in Biological, Biotechnology and Chemical Human Medicines under the National, Decentralized, Mutual Recognition, and Centralized Procedures, including Marketing Authorisation Applications, Variations and Renovations; Clinical Trials and Variations to Clinical Trials of Experimental Medicinal Products; BSE/TSE issues in the context of medical devices
 - Country: Portugal
5. Employer: Department of Biochemistry and Human Biology, Faculty of Pharmacy, University of Lisbon
 - Start date: 042007
 - End date: 022016
 - Position: Assistant Professor
 - Activities:
 - Teaching Biochemistry
 - Supervision of Degree and Post_Graduated Students (Master and PhD)
 - Country: Portugal
6. Employer: INFARMED – National Authority of Medicines and Health Products, IP
 - Start date: 072010
 - End date:
 - Position: Member of the Human Medicines Evaluation Committee (CAM)
 - Activities:
 - External quality assessor in Chemical and Biological Human Medicines under the National, Decentralized and Mutual Recognition Procedures, including Marketing Authorisation Applications, Variations and Renovations; Clinical Trials and Variations to Clinical Trials of Experimental Medicinal Products; BSE/TSE issues in the context of medical devices
 - Country: Portugal
7. Employer: Research Institute for Medicines (iMed.U.Lisboa) –Metabolism & Genetics Group, Faculty of Pharmacy, University of Lisbon
 - Start date: 072007
 - End date:
 - Position: Researcher
 - Activities:
 - Research in the areas of Molecular and Biochemical Bases of Inborn Errors of Metabolism; Energy Metabolism; Heterologous Expression of Human Proteins involved in lipid metabolism
 - Country: Portugal
8. Employer: INFARMED – National Authority of Medicines and Health Products, IP
 - Start date: 092004
 - End date: 072010
 - Position: Quality Assessor
 - Activities:
 - External quality assessor in Chemical and Biological Human Medicines under the National, Decentralized, Mutual Recognition procedures, including Marketing Authorisation Applications, variations and renovations; Clinical trials and variations of clinical trials of experimental medicinal products; BSE/TSE issues in the contexto of medical devices
 - Country: Portugal
9. Employer: Department of Biochemistry and Human Biology, Faculty of Pharmacy, University of Lisbon
 - Start date: 042002
 - End date: 032007

- Position: College / university teaching professional
 - Activities:
 - Teaching Biochemistry
 - Supervision of degree and post_graduated students (Master and PhD)
 - Country: Portugal
10. Employer: Molecular Pathogenesis Center – Unit of Molecular Biology & Experimental Biopathology – Molecular and Biochemical Bases of Inborn Errors of Metabolism, Faculty of Pharmacy, University of Lisbon
- Start date: 042002
 - End date: 072007
 - Position: Researcher
 - Activities:
 - Research in the Biochemical and Molecular Bases of Inborn Errors of Metabolism; Energy metabolism; Heterologous expression of human proteins involved in lipid metabolism
 - Country: Portugal
11. Employer: INFARMED – National Authority of Medicines and Health Products, IP
- Start date: 012001
 - End date: 042002
 - Position: Coordinator at the Technical_Scientific Evaluation Operational Unit of the Human Medicines Evaluation Department
 - Activities:
 - Management and coordination
 - Country: Portugal
12. Employer: Institute for the Financial and Information Technologies Management of the Health Ministry (IGIF), Health Ministry
- Start date: 2000
 - End date: 2001
 - Position: INFARMED´s Representative at the Analysis Commission for the Acquisition of Blood Derived Products (2000)
 - Activities:
 - Consultant
 - Country: Portugal
13. The European Agency for the Evaluation of Medicinal Products (EMA)
- Start date: 2000
 - End date: 2001
 - Position: Alternate Portuguese Member at the Biologics Working Party (BWP)
 - Activities:
 - Expert
 - Country: United Kingdom
14. The European Agency for the Evaluation of Medicinal Products (EMA)
- Start date: 2000
 - End date: 2000
 - Position: Portuguese member at the Tradenames Ad_Hoc Review Group of the Committee for Proprietary Medicinal Products (CPMP)
 - Activities:
 - Expert
 - Country: United Kingdom
15. Employer: Instituto Superior de Ciências da Saúde – Sul
- Start date: 101998
 - End date: 031999
 - Position: College / university teaching professional
 - Activities:
 - Teaching Cell Biology to Pharmaceutical Sciences students
 - Country: Portugal
16. Employer: INFARMED – National Authority of Medicines and Health Products, IP
- Start date: 041998
 - End date: 082001
 - Position: Regulatory Affairs at the Medicines Department
 - Activities:
 - Managements
 - All aspects of National, Mutual Recognition and Decentralized Procedures (Present at the monthly meetings of CPMP at EMA, London)
 - Country: Portugal
17. Employer: SDC Pharma, Lda
- Start date: 101997
 - End date: 041998
 - Position: Regulatory Affairs
 - Activities:
 - Regulatory Affairs _ preparation and submission of marketing authorisation applications of human medicines at INFARMED
 - Country: Portugal
18. European Medicines Agency (EMA) _ Patients' and Consumer's Working Party (PCWP)
- Start date: 032019
 - End date:
 - Position: CHMP representative (alternate)
 - Activities: Liason between CHMP and PCWP
 - Country: Netherlands
19. European Medicines Agency (EMA) _ Healthcare Professional's Working Party (HCPWP)
- Start date: 062016
 - End date:
 - Position: CHMP representative (member)
 - Activities: Liason between CHMP and HCPWP
 - Country: Netherlands
20. European Medicines Agency (EMA) _ Committee for Medicinal Products for Human Use (CHMP)
- Start date: 032016
 - End date:
 - Position: CHMP Alternate Member (PT)
 - Activities: Alternate member from Portugal. Quality assessor in Biological, Biotechnology and Chemical Human Medicines.
 - Country: United Kingdom

Education and training

1. Subject: Faculty of Pharmacy, University of Lisbon
 - Start date: 101993
 - End date: 111998

- Qualification: PhD in Pharmacy (Biochemistry)
 - Organisation:
 - Country: Portugal
2. Subject: Metabolism and Genetics Center, Faculty of Pharmacy, University of Lisbon
 - Start date: 1993
 - End date: 1997
 - Qualification: PhD Scholarship from the National Institute for Scientific and Technologic Research
 - Organisation:
 - Country: Portugal
 3. Subject: Academical Medical Centre, University of Amsterdam
 - Start date: 1994
 - End date: 1996
 - Qualification: PhD Scholarship from the National Institute for Scientific and Technologic Research
 - Organisation:
 - Country: Netherlands
 4. Subject: Metabolism and Genetics Center, Faculty of Pharmacy, University of Lisbon
 - Start date: 1991
 - End date: 1993
 - Qualification: Research Fellowship from the National Institute for Scientific Research in the Metabolism and Genetics Center
 - Organisation:
 - Country: Portugal
 5. Subject: Faculty of Pharmacy, University of Lisbon
 - Start date: 1985
 - End date: 1991
 - Qualification: Degree in Pharmaceutical Sciences (Clinical Chemistry)
 - Organisation:
 - Country: Portugal
 6. Subject: Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)
 - Start date: 112018
 - End date: 112018
 - Qualification: EU NTC _ Quality Assessment training for Clinical Trials
 - Organisation:
 - Country: Germany
 7. Subject: European Medicines Agency
 - Start date: 112018
 - End date:
 - Qualification: Workshop on quality support to accelerated access schemes (i.e. PRIME, Breakthrough Therapies) (webinar)
 - Organisation:
 - Country: United Kingdom
 8. Subject: European Medicines Agency
 - Start date: 092018
 - End date:
 - Qualification: EMA training on 'European Legislation on Advanced Therapies' (webinar)
 - Organisation:
 - Country: United Kingdom
 9. Subject: Faculty of Pharmacy, University of Porto
 - Start date: 072018
 - End date:
 - Qualification: European Drug Regulation and Advanced Therapies
 - Organisation:
 - Country:
 10. Subject: European Medicines Agency
 - Start date: 062018
 - End date:
 - Qualification: EU Network Regulatory Awareness Session on Medical devices (webinar)
 - Organisation:
 - Country: United Kingdom
 11. Subject: European Medicines Agency
 - Start date: 062018
 - End date:
 - Qualification: BSWP webinar training session 'Basics in Survival Analysis' (webinar e online)
 - Organisation:
 - Country: United Kingdom
 12. Subject: European Medicines Agency
 - Start date: 052018
 - End date:
 - Qualification: EMA webinar on regulatory science strategy (webinar)
 - Organisation:
 - Country: United Kingdom
 13. Subject:
 - Start date: 032018
 - End date:
 - Qualification: EU Network Regulatory awareness session on New Developments in the field of ATMPs (webinar)
 - Organisation:
 - Country:
 14. Subject: INFARMED – National Authority for Medicines and Health Products, I.P.
 - Start date: 112017
 - End date: 122017
 - Qualification: The risks of corruption and their prevention
 - Organisation:
 - Country: Portugal
 15. Subject: INFARMED – National Authority for Medicines and Health Products, I.P.
 - Start date: 112017
 - End date:
 - Qualification: Cibersecurity
 - Organisation:
 - Country: Portugal
 16. Subject: INFARMED – National Authority for Medicines and Health Products rodutos de Saúde, I.P.
 - Start date: 102017
 - End date: 102017
 - Qualification: Course on "Ethical, Transparency and Corruption Prevention in Public Administration
 - Organisation:

- Country: Portugal
- 17. Subject: National Institute of Administration _ General Department for Qualification of Employers of Public Administration
 - Start date: 092017
 - End date: 122017
 - Qualification: Certificate in Public Management (FORGEP)
 - Organisation:
 - Country: Portugal
- 18. Subject: European Medicines Agency
 - Start date: 092017
 - End date:
 - Qualification: EU Network Regulatory Awareness Session Navigating through Biosimilar Development (webinar)
 - Organisation:
 - Country: United Kingdom
- 19. Subject: European Medicines Agency
 - Start date: 092017
 - End date:
 - Qualification: Expert meeting on Adeno Associated Virus (AAV) gene therapy medicinal products (webinar)
 - Organisation:
 - Country: United Kingdom
- 20. Subject: EU_NTC/European Medicines Agency
 - Start date: 062017
 - End date: 062017
 - Qualification: Quality Working Party training for quality assessors (webinar)
 - Organisation:
 - Country: United Kingdom
- 21. Subject: European Medicines Agency
 - Start date: 062017
 - End date:
 - Qualification: EU network regulatory awareness session on Early Access (webinar)
 - Organisation:
 - Country: United Kingdom
- 22. Subject: European Medicines Agency
 - Start date: 042017
 - End date:
 - Qualification: Orphan Medicines Designation and development in Rare Diseases (webinar)
 - Organisation:
 - Country: United Kingdom
- 23. Subject: European Medicines Agency
 - Start date: 032017
 - End date:
 - Qualification: Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) joint workshop on personalised medicines
 - Organisation:
 - Country: United Kingdom
- 24. Subject: European Medicines Agency
 - Start date: 122016
 - End date:
 - Qualification: EMA Workshop on Adaptive pathways (webinar)
 - Organisation:
 - Country: United Kingdom
- 25. Subject: European Medicines Agency
 - Start date: 122016
 - End date:
 - Qualification: Assessors training on viral safety evaluation of biotechnological medicinal products (webinar)
 - Organisation:
 - Country: United Kingdom
- 26. Subject: EU_NTC/European Medicines Agency
 - Start date: 112016
 - End date: 112016
 - Qualification: EU_NTC: EU and International Assessor training on Biosimilars
 - Organisation:
 - Country: United Kingdom
- 27. Subject: European Medicines Agency
 - Start date: 112016
 - End date: 112016
 - Qualification: Workshop on scientific and regulatory challenges of genetically modified cell_based cancer immunotherapy products (webinar)
 - Organisation:
 - Country: United Kingdom
- 28. Subject: European Medicines Agency
 - Start date: 042016
 - End date:
 - Qualification: Orphan designation training for newcomers (webinar)
 - Organisation:
 - Country: United Kingdom
- 29. Subject: Faculty of Pharmacy, University of Lisbon
 - Start date: 022014
 - End date: 022014
 - Qualification: VI SPB Clinical Biochemistry Workshop & V SPDM Post_Graduate Training Course _ Peroxisomes and Mitochondria: Players in Cellular Metabolism
 - Organisation:
 - Country: Portugal
- 30. Subject: European Medicines Agency (EMA)
 - Start date: 042011
 - End date: 042011
 - Qualification: Training for Advanced Therapy Medicinal Products Assessors
 - Organisation:
 - Country: United Kingdom
- 31. Subject: Biophysics Portuguese Society
 - Start date: 102010
 - End date: 102010
 - Qualification: 9th Short Course of the Portuguese Biophysical Society – Protein Folding, Misfolding and Disease
 - Organisation:

- Country: Portugal
- 32. Subject: Life and Health Sciences Research Institute, School of Health Sciences, University of Minho
 - Start date: 062009
 - End date: 062009
 - Qualification: Gene Silencing using RNA interference: lectures and hands_on
 - Organisation:
 - Country: Portugal
- 33. Subject: Center for Neurosciences and Cell Biology, University of Coimbra
 - Start date: 052009
 - End date: 052009
 - Qualification: Integrated Approaches for the Study of Mitochondrial Dynamics
 - Organisation:
 - Country: Portugal
- 34. Subject: Center for Neurosciences and Cell Biology, University of Coimbra
 - Start date: 052009
 - End date: 052009
 - Qualification: International Courses on Toxicology 2009 – Mitochondria Between Life and Death
 - Organisation:
 - Country: Portugal
- 35. Subject: ITQB
 - Start date: 032009
 - End date: 032009
 - Qualification: International Workshop Protein Folding Diseases: From Metabolic Disorders to Neurodegeneration
 - Organisation:
 - Country: Portugal
- 36. Subject: Faculty of Sciences and Technology, Nova University of Lisbon, Department of Chemistry
 - Start date: 032007
 - End date: 032007
 - Qualification: Crystallography of Proteins
 - Organisation:
 - Country: Portugal
- 37. Subject: Institute for Membranes and Systems Biology and the Astbury Centre, University of Leeds
 - Start date: 032010
 - End date: 032010
 - Qualification: Masterclass on Systems Approaches to Membrane Proteins
 - Organisation:
 - Country: United Kingdom
- 38. Subject:
 - Start date: 062006
 - End date: 062006
 - Qualification: 1st International Workshop on Expression, Structure and Function of Membrane Proteins
 - Organisation:
 - Country: Italy
- 39. Subject: Portuguese Society of Metabolic Disorders, Faculty of Pharmacy, University of Lisbon
 - Start date: 112005
 - End date: 112005
 - Qualification: Post_Graduate Course of Inborn Errors of Metabolism – From the Biochemical and Molecular Bases to Clinics, Diagnosis, and Therapeutic Approaches: Mitochondrial Fatty Acid Beta_oxidation Disorders
 - Organisation:
 - Country: Portugal
- 40. Subject: ITQB
 - Start date: 092005
 - End date: 092005
 - Qualification: 1st ESF and MAX_INF2 Course on Membrane Proteins: The Rocky Road from Gene to Structure
 - Organisation:
 - Country: Portugal
- 41. Subject: Portuguese Society of Metabolic Disorders, Faculty of Pharmacy, University of Lisbon
 - Start date: 072005
 - End date: 072005
 - Qualification: Post_Graduate Course of Inborn Errors of Metabolism – From the Biochemical and Molecular Bases to Clinics, Diagnosis, and Therapeutic Approaches: Organic Acidurias
 - Organisation:
 - Country: Portugal
- 42. Subject: Portuguese Society of Metabolic Disorders, Faculty of Pharmacy, University of Lisbon
 - Start date: 052005
 - End date: 052005
 - Qualification: Post_Graduate Course of Inborn Errors of Metabolism – From the Biochemical and Molecular Bases to Clinics, Diagnosis, and Therapeutic Approaches: Defect of Urea Cycle
 - Organisation:
 - Country: Portugal
- 43. Subject: IST
 - Start date: 052005
 - End date: 052005
 - Qualification: Second Meeting of the COST Working Group Principles of Membrane Protein Folding and Stability
 - Organisation:
 - Country: Portugal
- 44. Subject: Portuguese Society of Metabolic Disorders, Faculty of Pharmacy, University of Lisbon
 - Start date: 042005
 - End date: 042005
 - Qualification: Post_Graduate Course of Inborn Errors of Metabolism – From the Biochemical and Molecular Bases to Clinics, Diagnosis, and Therapeutic Approaches: Defect of Pyruvate Dehydrogenase
 - Organisation:
 - Country:
- 45. Subject: Faculty of Pharmacy, University of Lisbon
 - Start date: 062003
 - End date: 062003
 - Qualification: International Symposium on Stem Cells and Regenerative
 - Organisation:
 - Country:
- 46. Subject: Institute Pasteur
 - Start date: 102000

- End date: 102000
 - Qualification: Pharmacogenetics and Pharmacogenomics
 - Organisation:
 - Country: France
47. Subject: IBC
- Start date: 092000
 - End date: 092000
 - Qualification: IBC's 9th Annual International Conference _ Protecting and Exploiting _ Utilising biotechnological patents to the full
 - Organisation:
 - Country: Denmark
48. Subject: The European Agency for the Evaluation of Medicinal Products (EMA)
- Start date: 052000
 - End date: 052000
 - Qualification: Human TSEs and Plasma Derived Medicinal Products
 - Organisation:
 - Country: United Kingdom
49. Subject: University of Essen
- Start date: 042000
 - End date: 042000
 - Qualification: First International Conference on Gene Technology & Skin Gene Therapy
 - Organisation:
 - Country: Germany
50. Subject: Agencia Española del Medicamento
- Start date: 111999
 - End date: 111999
 - Qualification: Meeting on the use of pharmacogenetics in drug development
 - Organisation:
 - Country: Spain
51. Subject: Paul Ehrlich Institut and NIBSC _ Paul Ehrlich Institut
- Start date: 101999
 - End date: 101999
 - Qualification: Development and Clinical Progress of DNA Vaccines
 - Organisation:
 - Country: Germany
52. Subject: European Association of the Plasma Products Industry (EAPPI) and European Plasma Fractionation Association (EPFA)
- Start date: 101999
 - End date: 101999
 - Qualification: 6th Annual EAPPI – EPFA _ Regulatory Affairs Symposium _ Quality & Safety of Plasma Products
 - Organisation:
 - Country: France
53. Subject: IIR
- Start date: 041999
 - End date: 041999
 - Qualification: Introduction to European Regulatory Affairs
 - Organisation:
 - Country: United Kingdom
54. Subject: Cambridge Healthtech Institute
- Start date: 021999
 - End date: 021999
 - Qualification: TSE Perception vs. Reality
 - Organisation:
 - Country: United States
55. Subject: Cambridge Healthtech Institute
- Start date: 021999
 - End date: 021999
 - Qualification: Blood Safety & Screening
 - Organisation:
 - Country: United States
56. Subject:
- Start date: 101998
 - End date: 101998
 - Qualification: 2nd European Course of Pre-Clinical Assessors
 - Organisation:
 - Country: Portugal
57. Subject: INFARMED
- Start date: 051998
 - End date: 051998
 - Qualification: Methodologies in Pharmacovigilance
 - Organisation:
 - Country: Portugal
58. Subject: Faculty of Sciences and Technology, Nova University of Lisbon, Department of Chemistry, Costa da Caparica, Portugal & Toxicology Institute, University of Tübingen , Germany
- Start date: 101992
 - End date: 101992
 - Qualification: High Performance Liquid Chromatography Professional Course
 - Organisation:
 - Country: Portugal

Additional information

Publications

22. Cunha J, **Ventura FV**, Charrueau C, Ribeiro AJ. Alternative routes for parenteral nucleic acid delivery and related hurdles: highlights in RNA delivery. *Expert Opin Drug Deliv.* 2024 Oct;21(10):1415-1439. doi: 10.1080/17425247.2024.2405207.
21. Madeira CA, Anselmo C, Costa JM, Bonito CA, Ferreira RJ, Santos DJVA, Wanders RJ, Vicente JB, **Ventura FV**, Leandro P. Functional and structural impact of 10 ACADM missense mutations on human medium chain acyl-Coa dehydrogenase. *Biochim Biophys Acta Mol Basis Dis.* 2023 Oct;1869(7):166766. doi: 10.1016/j.bbadis.2023.166766
20. Souto EB, Silva GF, Dias_Ferreira J, Zielinska A, **Ventura F**, Durazzo A, Lucarini M, Novellino E, Santini A. Nanopharmaceutics: Part I_Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU. *Pharmaceutics.* 2020 Feb 11;12(2):146. doi: 10.3390/pharmaceutics12020146.
19. Souto EB, Silva GF, Dias_Ferreira J, Zielinska A, **Ventura F**, Durazzo A, Lucarini M, Novellino E, Santini A. Nanopharmaceutics: Part I_Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics

in the EU. *Pharmaceutics*. 2020 Feb 11;12(2):146. doi: 10.3390/pharmaceutics12020146.

18. Janeiro P, Jotta R, Ramos R, Florindo C, **Ventura FV**, Vilarinho L, Tavares de Almeida I, Gaspar A. Follow up of fatty acid β oxidation disorders in expanded newborn screening era. *Eur J Pediatr*. 2019 Mar;178(3):387_394. doi: 10.1007/s00431_018_03315_2.

17. Pelfrene E, Harvey Allchurch M, Ntamabyaliro N, Nambasa V, **Ventura FV**, Nagercoil N, Cavaleri M. The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis. *PLoS Negl Trop Dis*. 2019 Jun 27;13(6):e0007381. doi: 10.1371/journal.pntd.0007381. doi: 10.1371/journal.pntd.0007381.

16. Bonito CA, Nunes J, Leandro J, Louro F, Leandro P, **Ventura FV**, Guedes RC. Unveiling the Pathogenic Molecular Mechanisms of the Most Common Variant (p.K329E) in Medium Acyl-CoA Dehydrogenase Deficiency by in Vitro and in Silico Approaches. *Biochemistry*. 2016. 55(51):7086_7098. doi: 10.1021/acs.biochem.6b00759.

15. Bonito CA, Leandro P, Guedes R, **Ventura FV**. Insights on Medium chain acyl-CoA dehydrogenase structure by Molecular Dynamics simulations. *Chemical Biology & Drug Design*. 2016. doi: 10.1111/cbdd.12755.

14. Houten SM, Violante S, **Ventura FV**, Wanders RJ. The Biochemistry and Physiology of Mitochondrial Fatty Acid β Oxidation and Its Genetic Disorders. *Annual Review Physiol*. 78:23_44, 2016. doi: 10.1146/annurev_physiol.021115_105045.

13. **Ventura FV**, Leandro P, Luz A, Rivera IA, Silva MF, Ramos R, Rocha H, Lopes A, Fonseca H, Gaspar A, Diogo L, Martins E, Leão Teles E, Vilarinho L, Tavares de Almeida I. Retrospective study of the medium chain acyl-CoA dehydrogenase deficiency in Portugal. *Clinical Genetics*. 2014. doi: 10.1111/cge.12227.

12. Violante S, Ijlst L, Te Brinke H, Koster J, Tavares de Almeida I, Wanders RJ, **Ventura FV**, Houten SM. Peroxisomes contribute to the acylcarnitine production when the carnitine shuttle is deficient. *Biochimica et Biophys Acta*. 1831(9):1467_74, 2013; doi: 10.1016/j.bbali.2013.06.007.

11. Violante S, Ijlst L, Ruiten J, Koster J, van Lenthe H, Duran M, de Almeida IT, Wanders RJ, Houten SM, **Ventura FV**. Substrate specificity of human carnitine acetyltransferase: Implications for fatty acid and branched chain amino acid metabolism. *Biochimica et Biophysica Acta*. 1832(6):773_9, 2013; doi: 10.1016/j.bbadis.2013.02.012.

10. Violante S, Ijlst L, Te Brinke H, Tavares de Almeida I, Wanders RJ, **Ventura FV**, Houten SM. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines. *FASEB J*. 27(5):2039_44, 2013; doi: 10.1096/fj.12_216689.

9. Violante S, Ijlst L, van Lenthe H, Tavares de Almeida I, Wanders RJ, **Ventura FV**. Carnitine Palmitoyltransferase 2: New Insights on the Substrate Specificity and Implications for Acylcarnitine Profiling. *Biochimica et Biophysica Acta* 1802: 728_732, 2010. doi:10.1016/j.bbadis.2010.06.002.

8. **Ventura FV**, Tavares de Almeida I, Wanders RJA. Inhibition of adenine nucleotide transport in rat liver mitochondria by long chain acyl coenzyme A β oxidation intermediates. *Biochemical and Biophysical Research Communications* 352: 873_878, 2007. doi:10.1016/j.bbrc.2006.11.109.

7. **Ventura FV**, Ruiten J, Ijlst L, Tavares de Almeida I, Wanders RJA. Differential inhibitory effect of long chain acyl-CoA esters on succinate and glutamate transport into rat liver mitochondria and its possible implications for long chain fatty acid oxidation defects. *Molecular Genetics and Metabolism* 86: 344_352, 2005. doi:10.1016/j.ymgme.2005.07.030.

6. **Ventura FV**, Costa CG, Ruiten JPN, Allers P, Ijlst L, Tavares de Almeida I, Duran M, Jakobs C, Wanders RJA. Quantitative acylcarnitine profiling of [^{13}C]palmitic acid β oxidation in human fibroblasts: an improved tool for the diagnosis of fatty acid oxidation defects. *Clinica Chimica Acta* 281: 1_17, 1999. doi:10.1016/S0009_8981(98)00188_0.

5. **Ventura FV**, Ruiten JPN, Ijlst L, Tavares de Almeida I, Wanders RJA. Lactic acidosis in long chain fatty acid β oxidation disorders. *Journal of Inherited Metabolic Disease* 21: 645_654, 1998. doi:10.1023/A:1005480516801.

4. **Ventura FV**, Ijlst L, Ruiten JPN, Ofman R, Costa CG, Jakobs C, Duran M, Tavares de Almeida I, Bieber L, Wanders RJA. Carnitine palmitoyltransferase II specificity towards β oxidation intermediates: evidence for a reverse carnitine cycle in mitochondria. *European Journal of Biochemistry* 253: 614_618, 1998. doi:10.1046/j.1432_1327.1998.2530614.x.

3. **Ventura FV**, Costa CG, Ijlst L, Dorland L, Duran M, Jakobs C, Tavares de Almeida I, Bieber L, Wanders RJA. Broad specificity of carnitine palmitoyltransferase II towards long chain acyl-CoA β oxidation intermediates and its practical approach to the synthesis of various long chain acylcarnitines. *Journal of Inherited Metabolic Disease* 20: 423_426, 1997. doi: 10.1023/A:1005315003913.

2. **Ventura FV**, Ruiten JPN, Ijlst L, Tavares de Almeida I, Wanders RJA. Inhibitory effect of 3-hydroxy acyl-CoAs and other long chain fatty acid β oxidation intermediates in mitochondrial oxidative phosphorylation. *Journal of Inherited Metabolic Disease* 19: 161_164, 1996. doi:10.1007/BF01799419.

1. **Ventura FV**, Ruiten JPN, Ijlst L, Tavares de Almeida I, Wanders RJA. Inhibition of oxidative phosphorylation by palmitoyl-CoA in digitonin permeabilized fibroblasts: implications for long chain fatty acid β oxidation disorders. *Biochimica et Biophysica Acta – Molecular Basis of Disease* 1272: 14_20, 1995. doi:10.1016/0925_4439(95)00064_B. Since 1996 published 19 original communications, in the form of abstract, in Scientific Meetings Proceedings published in International Journals

• Since 1992 presented/contributed for more than 24 oral communications (10 invited) at International (13) and Nacional (10) meetings

• Since 1993 published more than 50 original communications, in the form of panel in various International (34) and Nacional (13) meetings

Projects

- Understand to treat: Combining in vitro and in silico strategies to explore new therapeutic approaches to the most common mitochondrial fatty acid beta oxidation disorder (mFAOD) (PTDC/BIA_BQM/29570/2017) (Principal Investigator)
- Medium chain Acyl-Coenzyme A Dehydrogenase Deficiency: Functional and Structural Characterization of Mutant Proteins (SPDM; 2010_2011) (Principal Investigator)
- Production of a Stable Form of Human Phenylalanine Hydroxylase: Towards the 3D Structure Determination (PDTC/QUI/64023/2006; 2009_2012) (Team member)
- Inborn Errors of Metabolism: Aminoacidopathies and Organic Aciduria (PMCT/C/SAU/1540/92; 1992_1994)

(Team member)

- Aminoacidopathies: detection and chemical characterization of the Inborn Errors of the Aminoacids' Metabolism (INIC; 1991_1993) (Team member)

Memberships

- The Society for the Study of Inborn Errors of Metabolism (SSIEM) (1995_ 1999; 2007_2009; 2013_)
- Ordem dos Farmacêuticos, Sociedade Farmacêutica Lusitana (Sócio n.º L_8271_ Secção Regional de Lisboa) (since 1998)
- Portuguese Society of Metabolic Disorders (since 2002)
- Biochemistry Portuguese Society (since 2002)
- Biophysics Portuguese Society (since 2010)

Other Relevant Information

I have long been interested in the elucidation of the pathogenesis of mitochondrial fatty acid beta-oxidation (FAO) disorders, namely the interaction mechanisms between FAO, energy metabolism and the carnitine cycle. In the last years, she expanded her studies into the in vitro and in silico characterization of the wild-type and various disease-causing mutants of the medium-chain acyl-CoA dehydrogenase, an enzyme of FAO. The ultimate goal is to define structural-functional markers for the screening for small molecules able to rescue the variant enzymes showing in vitro to be affected by misfolding.